Guidelines

AUA Guidelines

Oncology

Prostate

• NEW! Salvage Therapy for Prostate Cancer (2024)
• Advanced Prostate Cancer (2023)
• Early Detection of Prostate Cancer/Prostate Cancer Screening (2023)
• Clinically Localized Prostate Cancer (2022)
• Adjuvant and Salvage Radiotherapy After Prostatectomy (2019)
• Early Detection of Prostate Cancer/Prostate Cancer Screening (2018)
• Clinically Localized Prostate Cancer (2017)

Bladder

• NEW! Muscle-invasive Bladder Cancer (2024)
• Non-muscle Invasive Bladder Cancer (2020)
• Microscopic Hematuria (2020)
• Muscle-invasive Bladder Cancer (2020)
• Muscle-invasive Bladder Cancer (2017)
• Non-muscle Invasive Bladder Cancer (2016)

Kidney

• Renal Mass and Localized Renal Cancer (2021)

Testicular

• (2019) Included in Testicular Tumours Chapter Notes

Upper Tract Urothelial Carcinoma

• Upper Tract Urothelial Carcinoma (2023)

Non-oncology

Andrology

• Priapism (2021)
• Testosterone Deficiency (2018)
• Erectile Dysfunction (2018)
• Peyronie's Disease (2015)

Functional

• Female Stress Urinary Incontinence (2023)
• Management of LUTS Attributed to BPH (2021)
• NEW! Overactive Bladder (2019)
• AUA/CUA Mesh Position Statement (2019)
• Incontinence after Prostate Therapy (2019)

Infertility

• AUA/ASRM Infertility (2020) included in Chapter Notes of
  • Diagnosis and Evaluation of Infertility
  • Management of Infertility

Infections and Inflammation

• AUA/CUA Recurrent UTI (2019)

Pediatrics

• Cryptorchidism (2018)
• Vesicoureteral Reflux (2017)

Stones

• Evaluation and Medical Management of Stones (2019)
• Stone Surgery (2016)

Other

• Urethral Stricture Disease (2023)
• NEW! Interstitial Cystitis/Bladder Pain Syndrome (2022)
• Urotrauma (2020)
• Male Urethral Stricture (2016)
• Vasectomy (2015)

Contribute

• Overactive Bladder (2024)
• Incontinence after Prostate Therapy (2024 Amendment)
• Non-muscle Invasive Bladder Cancer (2024 Amendment)
• Diagnosis and Treatment of Early Stage Testicular Cancer (2024 Amendment)
• Management of LUTS attributed to BPH (2023 Amendment)
• Neurogenic LUTD (2021)
• Disorders of ejaculation (2020)
• Antibiotic Prophylaxis (2019)

CUA Guidelines

Oncology

Prostate

• Castrate-resistant Prostate Cancer (2021)
• Androgen Deprivation Therapy: Adverse Events & Management (2021)
• Metastatic Castration-naive and Castration-sensitive Prostate Cancer (2020)
• Testosterone Suppression (2018)
• Prostate Cancer Screening (2017)
• Cancer Care Ontario: MRI in Prostate Cancer Diagnosis (2017)
• Prostate Cancer Active Surveillance (2015)

Bladder

• Non-muscle Invasive Bladder Cancer (2021)
• Advanced and Metastatic Urothelial Cancer (2019)
• Muscle-invasive Bladder Cancer (2019)
• Asymptomatic Microscopic Hematuria (2008)

Kidney

• Follow-up Localized RCC (2018)
• Cystic Renal Lesions (2017)
• Small Renal Masses (2015)
• Surgical Management of RCC (2014)
• RCC Genetic Screening (2013)

Non-oncology

Andrology

• Peyronie's Disease (2018)
• Erectile Dysfunction (2021)

Functional

• Neurogenic Lower Urinary Tract Dysfunction (2019)
• Male LUTS/BPH (2018)
• CUA/AUA Mesh Position Statement (2019)
• Overactive Bladder (2017)

Infections and Inflammation

• CUA/AUA Recurrent UTI (2019)
• Antibiotic Prophylaxis (2015)
• Chronic Scrotal Pain (2018)
• Interstitial Cystitis (2016)

Infertility

• Azoospermia (2015)

Pediatrics

• Circumcision (2018)
• Antenatal hydronephrosis (2017)
• Cryptorchidism (2017)
• Multicystic Dysplastic Kidney in the Neonate (2015)

Stones

• Evaluation and Medical Management of Stones (2016)
• Ureteral Calculi (2015)

Other

• Vasectomy (2022)
• Adrenal Mass (2011)
• Radiation-induced Hemorrhagic Cystitis (2018)
• VTE Prophylaxis (2019)
• Vasectomy (2016)

Contribute

• Ureteral calculi (2022)
• Pediatric bladder dysfunction (2021)
• Sporadic angiomyolipomas (2020)
• Male urethral stricture (2020)
• Catheter use (2020)
• Renal mass biopsy (2019)
• Pheochromocytoma surveillance (2019)
• Pediatric hemorrhagic cystitis (2019)